Facebook
X
LinkedIn
Forward
Building Capacity for Bispecific Antibodies in Community Cancer Centers: Creating a Road Map for Implementation in the Outpatient Setting
Overview
Bispecific antibodies are improving outcomes for patients with cancer, yet many centers do not have the infrastructure needed to deliver these therapies safely and consistently. This 2-hour accredited program will provide your multidisciplinary team with practical tools and processes to support implementation. A designated champion from your own center will help adapt the agenda and discussions to your team's priorities.
Through interactive presentations, case-based scenarios, and faculty panel discussions, participants will explore the steps needed to initiate the process and build the care models, protocols, and safety pathways tailored to your center's resources and patient population. Learners will leave with a clearer understanding of the path to implementation, the immediate next steps, and the common pitfalls to anticipate and avoid.
Learning Objectives
- Evaluate available clinical trial data and emerging real-world evidence supporting the efficacy and safety of bispecific antibody therapy across multiple myeloma, lymphoma, and select solid tumors
- Apply evidence-based strategies to mitigate and manage treatment-related adverse events with bispecific antibody therapy
- Discuss key components of outpatient clinic infrastructure—including workflow design, multidisciplinary coordination, safety readiness, and patient/caregiver education—needed to implement bispecific antibody therapy programs in community cancer centers
- Explain practical considerations for patient identification, education, and transition of care that enable successful outpatient implementation of bispecific antibody programs
Target Audience
This activity is intended for hematologists, oncologists, hematology/oncology advanced practice providers (NPs, PA, pharmacists and nurses), and practice administrators working in community cancer centers and/or outpatient clinics.
ATTENTION: This is a hybrid event. Those who wish to attend virtually will be provided with a link to join via computer, laptop or mobile device
Privacy Statement: For online registration, we take precautions to protect your information. When you submit sensitive information via the website, your information is protected both online and offline. In order to use this website, a user must first complete the registration form. During registration, a user is required to give certain information (such as name, email, mailing address, and payment information). This information is confidential and will only be used to contact you regarding your registration.
Course summary
- 1.00 AMA PRA Category 1 Credit™
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.
Horizon CME designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Commercial support: This activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc., Johnson & Johnson, and Amgen.
Please note: times are subject to change. Please check the syllabus for the most current version of the agenda upon arriving at the program.
All Times Listed are for the Easter Standard Time Zone
Tuesday, October 27, 2026 | |
| 5:30pm | Welcome & Introductions |
| 5:35pm | Part 1: Mapping the Bispecific Landscape From mechanism to management |
| 6:30pm | Part 2: Navigating the Roadmap Building a community outpatient bispecific clinic |
| 7:25pm | Closing From Roadmap to Action |
Faculty Presenters
Kimberly Gentry, PA-C (Moderator)
Clinical Director
Carolina Oncology Specialists
Hickory, NC
Christopher Ferreri, MD (Speaker)
Assistant Professor of Cancer Medicine, Wake Forest University School of Medicine
Plasma Cell Disorders Section, Division of Hematology, Atrium Health Levine Cancer Institute
Charlotte, NC
Christopher Ferreri, MD, is an Assistant Professor of Cancer Medicine at Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine in Charlotte, NC.
Board-certified in Internal Medicine, Hematology, and Medical Oncology, Dr. Ferreri specializes in plasma cell disorders and hematologic malignancies, including multiple myeloma, light chain amyloidosis, and Waldenstrom macroglobulinemia. His clinical and translational research focuses on advanced therapeutics and CAR T-cell therapy, work that has earned him both an American Society of Hematology Abstract Achievement Award and an International Myeloma Society Young Investigator Award.
Dr. Ferreri earned his medical degree from The Ohio State University, completed his residency at Duke University, and finished his fellowship training at The University of Texas MD Anderson Cancer Center, where he was named the Clinical Fellow of the Year.
Katelynn Granger, PharmD, BCOP (Speaker)
Malignant Hematology Clinical Pharmacist
Atrium Health at Levine Cancer Institute
Charlotte, NC
Katelynn Granger, PharmD, BCOP, is a Clinical Pharmacist at Atrium Health Levine Cancer Institute. Since completing pharmacy school at the UNC Eshelman School of Pharmacy and PGY1 and PGY2 Oncology Pharmacy Residency training at the Medical University of South Carolina Health in 2021, she has specialized in outpatient malignant and benign hematology. Her clinical interests include multiple myeloma, lymphoma, and the integration of bispecific antibodies into patient care.
Natasha Carrera, MHA
Associate Director, Service Line Management
Fred Hutchinson Cancer Center
Seattle, WA
Program Planning Committee
Kimberly Gentry, PA-C (Moderator)
Clinical Director
Carolina Oncology Specialists
Hickory, NC
Disclosures:
Those others involved in the planning of this activity disclosed no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.
Other Contributors
All other non-faculty contributors and others involved in the planning, development and editing/review of the content disclosed no relevant financial relationships with any entity producing, marketing, re-selling or distributing health care goods or services consumed by or used on patients.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
COPYRIGHT INFORMATION
Copyright© 2026 by Horizon CME. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from Horizon CME.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.
Horizon CME designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.